# Funda Meric‐Bernstam

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/funda-meric-bernstam/

## Facts

| Field | Value |
| --- | --- |
| Citations | 101,252 |
| Field | Cancer Genomics and Diagnostics |
| h-index | 146 |
| i10-index | 699 |
| Last Known Institution | The University of Texas MD Anderson Cancer Center |
| OpenAlex ID | https://openalex.org/A5076426660 |
| ORCID iD | https://orcid.org/0000-0001-6816-6072 |
| Works | 2,649 |

## Researcher papers

- [Efficacy of Larotrectinib in <i>TRK</i> Fusion–Positive Cancers in Adults and Children](https://scholariq.org/papers/efficacy-of-larotrectinib-in-i-trk-i-fusion-positive-cancers-in-adults-and/)
- [AACR Project GENIE: Powering Precision Medicine through an International Consortium](https://scholariq.org/papers/aacr-project-genie-powering-precision-medicine-through-an-international/)
- [KRAS <sup>G12C</sup> Inhibition with Sotorasib in Advanced Solid Tumors](https://scholariq.org/papers/kras-sup-g12c-sup-inhibition-with-sotorasib-in-advanced-solid-tumors/)
- [Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group](https://scholariq.org/papers/recommendations-for-the-use-of-next-generation-sequencing-ngs-for-patients-with/)
- [Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial](https://scholariq.org/papers/efficacy-and-safety-of-trastuzumab-deruxtecan-in-patients-with-her2-expressing/)
- [Efficacy of RAD001 (Everolimus) and Octreotide LAR in Advanced Low- to Intermediate-Grade Neuroendocrine Tumors: Results of a Phase II Study](https://scholariq.org/papers/efficacy-of-rad001-everolimus-and-octreotide-lar-in-advanced-low-to-intermediate/)
- [Breast Conservation After Neoadjuvant Chemotherapy: The M.D. Anderson Cancer Center Experience](https://scholariq.org/papers/breast-conservation-after-neoadjuvant-chemotherapy-the-m-d-anderson-cancer/)
- [Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes](https://scholariq.org/papers/classifying-colorectal-cancer-by-tumor-location-rather-than-sidedness-highlights/)
- [PIK3CA/PTEN Mutations and Akt Activation As Markers of Sensitivity to Allosteric mTOR Inhibitors](https://scholariq.org/papers/pik3ca-pten-mutations-and-akt-activation-as-markers-of-sensitivity-to-allosteric/)
- [Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC](https://scholariq.org/papers/comutations-and-krasg12c-inhibitor-efficacy-in-advanced-nsclc/)
- [First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2–Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non–Small-Cell Lung Cancer: TROPION-PanTumor01](https://scholariq.org/papers/first-in-human-phase-i-dose-escalation-and-dose-expansion-study-of-trophoblast/)
- [Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study](https://scholariq.org/papers/datopotamab-deruxtecan-in-advanced-or-metastatic-hr-her2-and-triple-negative/)

## Researcher topics

- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)

## Researcher university

- [The University of Texas MD Anderson Cancer Center](https://scholariq.org/institutions/the-university-of-texas-md-anderson-cancer-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.